Physician profile
Aimee Sutherland
NPI 1831692649
$3,095.74
in general payments reported to CMS, 2019-2025
24 companies · $2,075 in 2025
The $2,075 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.96 · 2022: $160 · 2023: $254 · 2024: $560 · 2025: $2,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,888.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $447.25 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $384.93 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $373.79 | 2024-2025 | Hyqvia, Cuvitru, Takhzyro |
| Astrazeneca Pharmaceuticals Lp | $267.30 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Alk-Abello, INC | $214.53 | 2023 | Standardized Mite D. Farinae, Timothy, Standardized, Ragwitek |
| Glaxosmithkline, LLC. | $202.07 | 2024-2025 | Nucala, Trelegy Ellipta |
| Pharming Healthcare, INC. | $189.56 | 2022-2025 | Ruconest |
| Ars Pharmaceuticals Operations, INC. | $160.69 | 2025 | Neffy |
| Genentech USA, INC. | $150.80 | 2024-2025 | Xolair |
| Leo Pharma INC. | $146.97 | 2025 | Adbry |
| Amgen INC. | $93.69 | 2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $85.07 | 2025 | |
| Insmed, INC. | $82.55 | 2025 | Brinsupri, Arikayce |
| Pfizer INC. | $68.45 | 2025 | |
| Octapharma USA, INC. | $41.55 | 2024-2025 | Octagam Immune Globulin (Human) |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $33.53 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $26.80 | 2024 | Ayvakit |
| Ionis Pharmaceuticals, INC. | $26.21 | 2025 | Dawnzera |
| Kedrion Biopharma, INC. | $24.85 | 2025 | Gammaked, Koate, Kedrab |
| Csl Behring | $20.76 | 2025 | Andembry |
| Hospira, INC. | $19.03 | 2024 | |
| Azurity Pharmaceuticals, INC. | $17.79 | 2025 | Alvesco |
| Lilly USA, LLC | $14.33 | 2024 | Ebglyss |
| Organon LLC | $3.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimee Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.